The Personalis Mission
Our mission is to help cancer patients by enabling the next generation of personalized immuno-oncology therapeutics and diagnostics through rigorous innovation.
It Starts with Comprehensive Tumor Immunogenomics
Personalis is partnering with biopharma to develop and commercialize the next generation of immuno-oncology therapeutics and diagnostics by providing high-accuracy, validated genomic sequencing and immuno-oncology-focused analytics.
We are a full business partner from early development, through clinical trials and commercialization, through scale-up of products after approval.
A Universal Biomarker Platform for Immuno-Oncology
ACE ImmunoID is designed to harmonize biomarker strategies across clinical and biomarker discovery programs. The platform combines our augmented exome and transcriptome assays with advanced analytics to provide a more complete, multidimensional view of the following key immuno-oncology areas:
The ACE Advantage
ACE (Accuracy and Content Enhanced) Technology forms the basis of all Personalis platforms. ACE improves processes from nucleic acid preparation, to sequencing, to analytics.
Personalis Receives Approval from the New York State Dept. of Health for Use of its ACE ImmunoID™ Platform in Cancer Immunotherapeutic Clinical Trials
Personalis Launches ImmunogenomicsID™ for Multidimensional Immuno-Oncology Biomarker Analysis as the Latest Enhancement to the ACE ImmunoID™ Platform
READY TO ACCELERATE YOUR IMMUNO-ONCOLOGY STRATEGY?